Quantcast

Latest Actavis Stories

2014-07-11 16:23:31

DUBLIN, July 11, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis(®), which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to...

2014-07-08 16:25:34

DUBLIN, July 8, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dalfampridine Extended-release Tablets, 10 mg. Actavis' ANDA product is a generic version of Acorda Therapeutics' Ampyra(®), which is indicated as a treatment to improve walking in patients with multiple sclerosis. Acorda Therapeutics, Inc. filed suit against Actavis on...

2014-07-02 16:24:40

HAYWARD, Calif., July 2, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed. The acquisition includes one product marketed under an Abbreviated New Drug Application (ANDA) - Ursodiol tablet - and one approved ANDA that is not yet marketed - Lamotrigine orally...

2014-07-02 08:27:20

DUBLIN, July 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. In connection with...

2014-07-02 08:26:52

DUBLIN, July 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the final results of the elections made by stockholders of Forest Laboratories, Inc. ("Forest") regarding their preference as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest. As previously announced, on July 1, 2014, Actavis completed its acquisition of Forest, pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated February 17, 2014, by...

2014-07-01 08:31:15

- Paul M. Bisaro Named Executive Chairman - DUBLIN, July 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the appointment of three new members to the Company's Board of Directors, including Actavis' newly appointed CEO and President, Brenton L. Saunders. The Company also announced that Paul M. Bisaro, formerly the Chairman and Chief Executive Officer of Actavis, has been named to the newly created position of Executive Chairman of the Board of Actavis plc. The...

2014-07-01 08:30:06

- Creates an Innovative New Model in Specialty Pharmaceuticals Leadership - DUBLIN, July 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity transaction currently valued at approximately $28 billion. The combination creates one of the world's fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015. In...

2014-06-30 16:27:07

DUBLIN and NEW YORK, June 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis' proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest's agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the...

2014-06-30 08:30:53

DUBLIN and NEW YORK, June 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavis' pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1(st),...

2014-06-30 08:30:28

DUBLIN, June 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to release second quarter 2014 financial results on Tuesday, August 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related